EQUITY RESEARCH MEMO
Zanteris
Generated 5/11/2026
Executive Summary
Conviction (model self-assessment)20/100
Zanteris is a private French company founded in 2016, specializing in clinical project and vendor management services for the pharmaceutical industry, with a focus on oncology and drug discovery. Based in Paris, the company positions itself as a 'go-to expert' for seamless coordination and successful execution of clinical projects. However, the public information is limited; no pipeline, funding, or stage details are available. The description suggests a service-oriented model rather than a drug developer, which may limit its upside as a traditional biotech investment. Without disclosed assets or partnerships, Zanteris appears to be an early-stage service provider with an unclear competitive advantage.
Locked sections
- · Pipeline Analysis
- · Competitive Landscape
- · Catalyst Calendar (full 12-month)
- · Bull Case
- · Bear Case
- · Counterfactual Scenarios
- · Valuation Notes
- · SEC Filing Highlights
- · Insider Activity
- · Literature Watch
- · Patent Landscape
- · Mechanism Cluster Map
- · Audio Briefing (5 min)